Search

Galectin Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

3.96 2.59

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.5300000000000002

Max

3.94

Schlüsselkennzahlen

By Trading Economics

Einkommen

-4.1M

-9.1M

EPS

-0.14

Angestellte

9

EBITDA

2.2M

-827K

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+198.91% upside

Dividenden

By Acuity

Nächstes Ergebnis

13. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

39M

354M

Vorheriger Eröffnungskurs

1.37

Vorheriger Schlusskurs

3.96

Nachrichtenstimmung

By Acuity

50%

50%

150 / 340 Ranking in Healthcare

Galectin Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Aug. 2026, 23:01 UTC

Shares of Galectin Therapeutics Inc. are lower in after-market trading, with notable volatility and a decline since Monday's close.

21. Aug. 2026, 19:16 UTC

Galectin Therapeutics Inc shares are higher today, maintaining a position above the 20-day moving average and near the upper end of their one-month range.

20. Aug. 2026, 20:06 UTC

Galectin Therapeutics Inc. shares are lower today, continuing a decline since Wednesday. The price remains above its 20-day moving average.

18. Aug. 2026, 19:56 UTC

Galectin Therapeutics Inc. shares are higher today, advancing since Monday's close despite earlier pulling back from session lows. The stock remains above its 20-day moving average.

17. Aug. 2026, 19:56 UTC

Galectin Therapeutics Inc. shares are trading higher, recovering from an earlier low and positioned above the 20-day moving average. No specific news was identified.

14. Aug. 2026, 19:21 UTC

News

Galectin Therapeutics reports a net loss of $9.2 million for Q2, missing estimates, contributing to a decline in shares during the session.

13. Aug. 2026, 20:02 UTC

Galectin Therapeutics Inc shares are higher during Thursday's session, reflecting strong trading activity and unusually high market volume, despite lacking specific company news.

12. Aug. 2026, 19:42 UTC

Galectin Therapeutics Inc shares are rising Wednesday amid high trading volume, maintaining an upward trend since Tuesday's close despite pulling back from earlier session highs.

11. Aug. 2026, 19:56 UTC

Galectin Therapeutics Inc shares are lower today amid routine fluctuations and no specific news. The stock is near the lower end of its one-month trading range.

10. Aug. 2026, 20:02 UTC

Galectin Therapeutics Inc shares are lower today, reflecting a significant decline since Friday amid high trading volume and cautious investor sentiment following a weak jobs report.

8. Aug. 2026, 00:01 UTC

Galectin Therapeutics Inc shares are higher in after-market hours, reflecting strong buying activity. The stock has recovered from an early session low.

7. Aug. 2026, 23:01 UTC

Galectin Therapeutics Inc shares are higher in after-market hours, recovering from earlier losses amid favorable broader market conditions and a declining unemployment rate.

6. Aug. 2026, 22:06 UTC

Galectin Therapeutics Inc shares are lower in after-market trading, continuing a trend below their 20-day moving average amid a significant decline since last month.

5. Aug. 2026, 23:02 UTC

Galectin Therapeutics Inc shares are higher in after-market trading, despite no specific news driving the movement. The stock showed significant volatility during the session.

4. Aug. 2026, 20:03 UTC

News

Galectin Therapeutics announced a $105.8 million debt-to-equity conversion but shares are lower today after an early peak. Trading volume is unusually high.

3. Aug. 2026, 19:46 UTC

Galectin Therapeutics Inc is higher today, continuing an upward trend since Friday's close, despite pulling back from a session high. No specific news was identified.

31. Juli 2026, 21:51 UTC

Galectin Therapeutics Inc is lower in after-market trading, influenced by broader market trends. The asset has faced three consecutive sessions of declines.

30. Juli 2026, 20:10 UTC

Galectin Therapeutics Inc is lower today, breaking a trend of higher daily closes. Increased market volume accompanies the decline amid broader market volatility.

29. Juli 2026, 18:58 UTC

Galectin Therapeutics Inc shares are higher today, continuing an upward trend since Tuesday's close. The stock remains below its 20-day moving average.

28. Juli 2026, 17:46 UTC

Galectin Therapeutics Inc shares are lower today, continuing a decline since Monday's close, amid broader market caution following significant drops in Asian indices.

27. Juli 2026, 16:32 UTC

Galectin Therapeutics Inc shares are lower today, reflecting a notable decline since Friday. The stock has seen unusually high trading volume amid broader market sentiment.

24. Juli 2026, 20:02 UTC

Galectin Therapeutics Inc is lower today, marking its ninth consecutive session of declines. The stock remains below its 20-day moving average.

22. Juli 2026, 19:01 UTC

Galectin Therapeutics Inc. shares are trading lower, following a peak earlier in the session. High trading volume indicates increased investor activity.

21. Juli 2026, 17:16 UTC

Galectin Therapeutics Inc. shares are lower today, continuing a five-session decline and trading significantly below the 20-day moving average. No specific news was identified.

20. Juli 2026, 20:06 UTC

Galectin Therapeutics Inc shares are lower today, continuing a trend of five consecutive daily declines amid broader market volatility linked to geopolitical tensions.

Peer-Vergleich

Kursveränderung

Galectin Therapeutics Inc Prognose

Kursziel

By TipRanks

198.91% Vorteil

12-Monats-Prognose

Durchschnitt 11 USD  198.91%

Hoch 11 USD

Tief 11 USD

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Galectin Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

1 ratings

1

Buy

0

Halten

0

Sell

Stimmung

By Acuity

150 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Galectin Therapeutics Inc

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
help-icon Live chat